AEMD
Aethlon Medical, Inc.
Medical - Devices
Market Cap$371K
5Y Perf.-99.8%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
AEMD vs XTLB
Revenue, margins, valuation, and 5-year total return — side by side.
XTLB
XTL Biopharmaceuticals Ltd.
Biotechnology
Market Cap$358K
5Y Perf.-39.4%
AEMD vs XTLB — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | AEMD | XTLB |
|---|---|---|
| Industry | Medical - Devices | Biotechnology |
| Market Cap | $371K | $358K |
| Revenue (TTM) | $0.00 | $451K |
| Net Income (TTM) | $-2.03B | $-1M |
| Gross Margin | — | 26.4% |
| Operating Margin | — | -481.6% |
| Total Debt | $650K | $138K |
| Cash & Equiv. | $6M | $371K |
AEMD vs XTLB — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
AEMD
XTLB
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| Aethlon Medical, In… (AEMD) | 100 | 0.2 | -99.8% |
| XTL Biopharmaceutic… (XTLB) | 100 | 60.6 | -39.4% |
Price return only. Dividends and distributions are not included.
Quick Verdict: AEMD vs XTLB
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: XTLB leads in 3 of 6 categories, making it the strongest pick for growth and revenue expansion and recent price momentum and sentiment. Aethlon Medical, Inc. is the stronger pick specifically for profitability and margin quality and capital preservation and lower volatility. As sector peers, any of these can serve as alternatives in the same allocation.
AEMD
Aethlon Medical, Inc.
The Income Pick
AEMD is the clearest fit if your priority is income & stability and sleep-well-at-night.
- beta 1.46
- Lower volatility, beta 1.46, Low D/E 12.7%, current ratio 3.13x
- Beta 1.46, current ratio 3.13x
Best for: income & stability and sleep-well-at-night
XTLB
XTL Biopharmaceuticals Ltd.
The Growth Play
XTLB carries the broadest edge in this set and is the clearest fit for growth exposure and long-term compounding.
- EPS growth 45.5%
- -84.5% 10Y total return vs AEMD's -100.0%
- -173.2% revenue growth vs AEMD's -177.7%
Best for: growth exposure and long-term compounding
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | XTLB | -173.2% revenue growth vs AEMD's -177.7% |
| Quality / Margins | AEMD | 3.9% margin vs XTLB's -227.7% |
| Stability / Safety | AEMD | Beta 1.46 vs XTLB's 1.71 |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | XTLB | -43.6% vs AEMD's -92.2% |
| Efficiency (ROA) | XTLB | -17.7% ROA vs AEMD's -25.2%, ROIC -54.1% vs -9.1% |
AEMD vs XTLB — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
FY 2022
Segment breakdown not available.
AEMD vs XTLB — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLXTLBLAGGINGAEMD
AEMDAethlon Medical, Inc.
1leads
XTLBXTL Biopharmaceutical…
3leads
6 Total Categories
CATEGORYLEADERvs AEMDMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
AEMD1/1
Valuation MetricsMultiples, price ratios, and targets
XTLB2/2
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
XTLB7/8
Total Returns1Y, 3Y, 5Y total returns with dividends
XTLB6/6
Risk & VolatilityBeta, volatility, and downside exposure
Tied
—
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
AEMD leads this category, winning 1 of 1 comparable metric.
Income & Cash Flow (Last 12 Months)
XTLB and AEMD operate at a comparable scale, with $451,000 and $0 in trailing revenue.
| Metric | AEMDAethlon Medical, … | XTLBXTL Biopharmaceut… |
|---|---|---|
| RevenueTrailing 12 months | $0 | $451,000 |
| EBITDAEarnings before interest/tax | -$5M | -$1M |
| Net IncomeAfter-tax profit | -$2.0B | -$1M |
| Free Cash FlowCash after capex | -$5.3B | $0 |
| Gross MarginGross profit ÷ Revenue | — | +26.4% |
| Operating MarginEBIT ÷ Revenue | — | -4.8% |
| Net MarginNet income ÷ Revenue | — | -2.3% |
| FCF MarginFCF ÷ Revenue | — | -3.7% |
| Rev. Growth (YoY)Latest quarter vs prior year | — | — |
| EPS Growth (YoY)Latest quarter vs prior year | +71.5% | +20.0% |
AEMD leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
XTLB leads this category, winning 2 of 2 comparable metrics.
Valuation Metrics
| Metric | AEMDAethlon Medical, … | XTLBXTL Biopharmaceut… |
|---|---|---|
| Market CapShares × price | $371,480 | $357,581 |
| Enterprise ValueMkt cap + debt − cash | -$4M | $124,581 |
| Trailing P/EPrice ÷ TTM EPS | -0.03x | -0.34x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | — | 0.79x |
| Price / BookPrice ÷ Book value/share | 0.07x | 0.07x |
| Price / FCFMarket cap ÷ FCF | — | — |
XTLB leads this category, winning 2 of 2 comparable metrics.
Profitability & Efficiency
XTLB leads this category, winning 7 of 8 comparable metrics.
Profitability & Efficiency
XTLB delivers a -25.5% return on equity — every $100 of shareholder capital generates $-26 in annual profit, vs $-30 for AEMD. XTLB carries lower financial leverage with a 0.03x debt-to-equity ratio, signaling a more conservative balance sheet compared to AEMD's 0.13x.
| Metric | AEMDAethlon Medical, … | XTLBXTL Biopharmaceut… |
|---|---|---|
| ROE (TTM)Return on equity | -30.2% | -25.5% |
| ROA (TTM)Return on assets | -25.2% | -17.7% |
| ROICReturn on invested capital | -9.1% | -54.1% |
| ROCEReturn on capital employed | -157.3% | -50.7% |
| Piotroski ScoreFundamental quality 0–9 | 3 | 3 |
| Debt / EquityFinancial leverage | 0.13x | 0.03x |
| Net DebtTotal debt minus cash | -$5M | -$233,000 |
| Cash & Equiv.Liquid assets | $6M | $371,000 |
| Total DebtShort + long-term debt | $649,751 | $138,000 |
| Interest CoverageEBIT ÷ Interest expense | -939.14x | -13.31x |
XTLB leads this category, winning 7 of 8 comparable metrics.
Total Returns (Dividends Reinvested)
XTLB leads this category, winning 6 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in XTLB five years ago would be worth $2,369 today (with dividends reinvested), compared to $18 for AEMD. Over the past 12 months, XTLB leads with a -43.6% total return vs AEMD's -92.2%. The 3-year compound annual growth rate (CAGR) favors XTLB at -12.9% vs AEMD's -79.6% — a key indicator of consistent wealth creation.
| Metric | AEMDAethlon Medical, … | XTLBXTL Biopharmaceut… |
|---|---|---|
| YTD ReturnYear-to-date | -15.6% | +35.4% |
| 1-Year ReturnPast 12 months | -92.2% | -43.6% |
| 3-Year ReturnCumulative with dividends | -99.2% | -33.9% |
| 5-Year ReturnCumulative with dividends | -99.8% | -76.3% |
| 10-Year ReturnCumulative with dividends | -100.0% | -84.5% |
| CAGR (3Y)Annualised 3-year return | -79.6% | -12.9% |
XTLB leads this category, winning 6 of 6 comparable metrics.
Risk & Volatility
Evenly matched — AEMD and XTLB each lead in 1 of 2 comparable metrics.
Risk & Volatility
AEMD is the less volatile stock with a 1.46 beta — it tends to amplify market swings less than XTLB's 1.71 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. XTLB currently trades 31.6% from its 52-week high vs AEMD's 6.8% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | AEMDAethlon Medical, … | XTLBXTL Biopharmaceut… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.46x | 1.71x |
| 52-Week HighHighest price in past year | $35.20 | $10.28 |
| 52-Week LowLowest price in past year | $1.36 | $1.05 |
| % of 52W HighCurrent price vs 52-week peak | +6.8% | +31.6% |
| RSI (14)Momentum oscillator 0–100 | 60.1 | 67.4 |
| Avg Volume (50D)Average daily shares traded | 42K | 2.4M |
Evenly matched — AEMD and XTLB each lead in 1 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
| Metric | AEMDAethlon Medical, … | XTLBXTL Biopharmaceut… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | — |
| Price TargetConsensus 12-month target | — | — |
| # AnalystsCovering analysts | — | — |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
XTLB leads in 3 of 6 categories (Valuation Metrics, Profitability & Efficiency). AEMD leads in 1 (Income & Cash Flow). 1 tied.
Best OverallXTL Biopharmaceuticals Ltd. (XTLB)Leads 3 of 6 categories
Loading custom metrics...
AEMD vs XTLB: Frequently Asked Questions
6 questions · data-driven answers · updated daily
01Which is the better long-term investment — AEMD or XTLB?
Over the past 5 years, XTL Biopharmaceuticals Ltd.
(XTLB) delivered a total return of -76. 3%, compared to -99. 8% for Aethlon Medical, Inc. (AEMD). Over 10 years, the gap is even starker: XTLB returned -84. 5% versus AEMD's -100. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
02Which is safer — AEMD or XTLB?
By beta (market sensitivity over 5 years), Aethlon Medical, Inc.
(AEMD) is the lower-risk stock at 1. 46β versus XTL Biopharmaceuticals Ltd. 's 1. 71β — meaning XTLB is approximately 17% more volatile than AEMD relative to the S&P 500. On balance sheet safety, XTL Biopharmaceuticals Ltd. (XTLB) carries a lower debt/equity ratio of 3% versus 13% for Aethlon Medical, Inc. — giving it more financial flexibility in a downturn.
03Which has better profit margins — AEMD or XTLB?
Aethlon Medical, Inc.
(AEMD) is the more profitable company, earning 0. 0% net margin versus -227. 7% for XTL Biopharmaceuticals Ltd. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: AEMD leads at 0. 0% versus -481. 6% for XTLB. At the gross margin level — before operating expenses — XTLB leads at 0. 7%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
04Which pays a better dividend — AEMD or XTLB?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
05Is AEMD or XTLB better for a retirement portfolio?
For long-horizon retirement investors, Aethlon Medical, Inc.
(AEMD) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding. XTL Biopharmaceuticals Ltd. (XTLB) carries a higher beta of 1. 71 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (AEMD: -100. 0%, XTLB: -84. 5%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
06What are the main differences between AEMD and XTLB?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.
Closest Rival
Compare XTLB vs NRXP
NRXP is one of the most direct listed alternatives to XTLB.
Segment Rival
Compare AEMD vs EKSO
EKSO overlaps with AEMD in an adjacent operating segment worth comparing.
Expand Peer Set
Expand With SIGA + NRXP
SIGA and NRXP are the strongest missing peers across the current compare set.